Precision BioSciences (DTIL) Tops Q2 EPS by 40c; Reports Cash and Cash Equivalents of $160.5M

Precision BioSciences (NASDAQ: DTIL) reported Q2 EPS of ($0.19), $0.40 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $24 million versus the consensus estimate of $6.02 million.

For earnings history and earnings-related data on Precision BioSciences (DTIL) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Piper Sandler on Fervo Energy (FRVO): 'Capital Access Supports Potential Upside'